TrialCancer science2021

Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.

Koji Izutsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.